A series of social media posts and articles are claiming that pharmaceutical company Merck has said that it’s better to get COVID-19 and recover than to get the vaccine.
An article from True Defender is headlined: “Merck Stops COVID Vaccine: ‘Studies Showed People Better Off Catching Virus and Recovering!’” An article from a site called Summit News has a similar headline: “Merck Scraps COVID Vaccines; Says It’s More Effective To Get The Virus And Recover.”
While the text of the Summit News article is fairly straightforward, these headlines are misleading and missing context.
It’s true that Merck is no longer developing a COVID-19 vaccine, and the company did disclose that its vaccine candidates showed immune responses “inferior to those seen following natural infection,” but the company also explained that other vaccines, already approved and being distributed, are more effective. Nowhere does the company suggest it’s better to catch the virus and recover.
Merck explained its decision in a statement from January 25: “This decision follows Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines.” Merck plans to research and develop “two therapeutic candidates” instead of vaccines.
If you have a claim you would like to see us fact check, please send us an email at factcheck@thedispatch.com. If you would like to suggest a correction to this piece or any other Dispatch article, please email corrections@thedispatch.com.
Please note that we at The Dispatch hold ourselves, our work, and our commenters to a higher standard than other places on the internet. We welcome comments that foster genuine debate or discussion—including comments critical of us or our work—but responses that include ad hominem attacks on fellow Dispatch members or are intended to stoke fear and anger may be moderated.
You are currently using a limited time guest pass and do not have access to commenting. Consider subscribing to join the conversation.
With your membership, you only have the ability to comment on The Morning Dispatch articles. Consider upgrading to join the conversation everywhere.